FDA Approves Rexulti For Agitation Associated With Dementia Due To Alzheimer's

The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.
The U.S. Food and Drug Administration announced the supplemental approval of Rexulti (brexpiprazole) oral tablets to treat agitation associated with dementia due to Alzheimer's disease.

First Treatment for Agitation Associated With Alzheimer Disease Dementia Approved by FDA

Otsuka, Lundbeck's Rexulti nabs new use in Alzheimer's disease agitation

FDA nod for Rexulti sNDA in treatment of Alzheimer's agitation

FDA Approves Rexulti for Agitation Associated With Dementia Due to Alzheimer's Disease

FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia Due to Alzheimer's Disease

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer's Disease

Rexulti On Track To Add Claim For Alzheimer's Dementia Agitation Following US Panel Nod :: Pink Sheet

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

FDA Approves First Drug to Treat Dementia-Associated Agitation in AD Patients

Otsuka and Lundbeck Issue Statement on REXULTI for Alzheimer's

For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

FDA approves first drug to treat agitation linked with Alzheimer's Disease